Nanophase Technologies Corporation (NANX) |
|
Price: $0.6400
$-0.06
-8.571%
|
Day's High:
| $0.7
| Week Perf:
| -14.67 %
|
Day's Low: |
$ 0.60 |
30 Day Perf: |
-29.67 % |
Volume (M): |
12 |
52 Wk High: |
$ 1.80 |
Volume (M$): |
$ 8 |
52 Wk Avg: |
$1.15 |
Open: |
$0.70 |
52 Wk Low: |
$0.32 |
|
|
Market Capitalization (Millions $) |
32 |
Shares
Outstanding (Millions) |
50 |
Employees |
46 |
Revenues (TTM) (Millions $) |
37 |
Net Income (TTM) (Millions $) |
-4 |
Cash Flow (TTM) (Millions $) |
1 |
Capital Exp. (TTM) (Millions $) |
2 |
Nanophase Technologies Corporation
Nanophase Technologies Corporation is an advanced materials and applications
developer and commercial manufacturer with an integrated family of materials
technologies. We produce engineered nano and sub-micron materials for use in
a variety of diverse markets: personal care including sunscreens, architectural
coatings, industrial coating applications, abrasion-resistant additives, plastics
additives, medical diagnostics, energy and a variety of surface finishing technologies
(polishing) applications, including optics.
While our origin is based on the creation of nanoscale metal oxide products,
we have expanded our offerings to include larger but still sub-micron materials.
We have developed techniques for managing attributes including particle size,
shape, surface coatings, and other valuable aspects of the material. Our focus
is on customer need where we believe we have an advantage, as opposed to finding
uses for one particular technology. Additionally, as the format of delivery
is important to customers, we have developed proprietary capabilities for dispersing
our materials into both aqueous (water-based) and solvent-based liquid media.
These capabilities allow us to better integrate with the customer’s need
and application. Finally, we have expanded our offerings beyond active ingredients
to include targeted full formulations of skin care products, marketed and sold
by our wholly-owned subsidiary, Solésence ™ LLC.
We target markets in which we believe practical solutions may be found using
our products. We work closely with current and potential customers in these
target markets to identify their material and performance requirements. We market
our materials to various end-use applications manufacturers and our Solésence
™ solutions to cosmetic and skin care brands. Recently developed technologies
have made certain new products possible and opened potential new markets. We
expect growth in end-user (manufacturing customers, including customers of our
customers) adoption in 2017 and beyond. Our initiatives in targeted market areas
are progressing at differing rates of speed, but we have been broadly moving
through testing and development cycles, and in a number of cases believe we
are approaching first revenue or next stage revenue with particular customers
in the industries referenced above. During 2015 we were granted a patent on
a new type of particle surface treatment (coating), which became the cornerstone
of our new product development in personal care, with first revenue recognized
during 2016 and the creation of our Solésence ™ LLC subsidiary
to manufacture and sell fully developed solutions to targeted customers in the
skin care industry, in addition to the additives we have traditionally sold
in the personal care area.
We have created a leading commercial approach to the application of our integrated
materials technologies designed to deliver an optimal engineered solution for
a target market or specific customer application. With respect to our products,
we have complete capability from application development and laboratory samples
through pilot production and, finally, commercial production currently at rates
as high as hundreds of metric tons per year for individual products. We have
development and application laboratories and manufacturing capacity in two locations
in the Chicago area. Our manufacturing is based on Lean Six Sigma discipline
and is certified to ISO 9001, American National Standard, Quality Management
System Requirements; ISO 14001, American National Standard, Environmental Management
System Requirements; and is compliant with current Good Manufacturing Practices
(“cGMP”) for products under U.S. Food and Drug Administration (“FDA”)
regulation.
We have undergone a strategic shift during recent years toward penetrating
key markets via interactive applications development with end-use customers
in these markets. We also supply both nanoscale and larger materials, based
on market requirement. We believe this strategy leverages the applications development
expertise we have cultivated over the last several years and best positions
us to build direct sales to end-use customers, in addition to translating these
advantages through our market partners.
Our efforts in research and development, process engineering and advanced engineering
groups are focused in three major areas: 1) application development for our
products; 2) creating or obtaining additional core material technologies and/or
materials that have the capability to serve multiple markets; and 3) continuing
to improve our core technologies to improve manufacturing operations and reduce
costs.
Most of our research and development is directly related to applications development.
We endeavor to either meet specific customer needs or to develop applications
solutions to address unmet needs in a particular market where we believe our
materials will offer a distinct performance advantage. We believe that aggressively
pursuing applications in targeted areas will help us compete as a technical
and commercial innovator using our materials expertise, and more importantly,
become perceived as a solutions provider by our customers and not simply as
another materials supplier.
Company Address: 1319 Marquette Drive Romeoville 60446 IL
Company Phone Number: 771-6708 Stock Exchange / Ticker: NANX
NANX is expected to report next financial results on March 28, 2024. |
|
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Safety Shot Inc
Safety Shot Inc (SHOT) recently reported a disastrous fiscal period, marked by significant decline in revenue and an expanded net deficit per share compared to the previous reporting season. This article aims to delve deeper into SHOT's financial performance and provide an explanation for the contrasting scenario in the Personal and Household Products sector, which witnessed a modest improvement in the third quarter of 2023. Revenue Decline and Net Deficit per Share Expansion SHOT experienced a staggering decline in revenue during the most recent fiscal period, with a slump of -69.158% to $0.48 million. This decline is significant when compared to the same reporting season a year ago. Additionally, the net deficit per share has expanded to $-0.26, a considerable increase from the previous year.
|
Dswiss Inc
DQWS, a leading company in the industry, recently released its financial results for the period ending September 30, 2023. The figures present an intriguing story of fluctuating revenues, declining net earnings, and contrasting inventory and accounts receivable levels. As we delve into the details, it becomes critical to assess how these numbers may impact the future of DQWS. Challenging Revenue Trend: The most significant observation in DQWS's financial report is the -41.637% decline in revenue compared to the previous year, amounting to $0.43 million in the current reporting period, down from $0.73 million a year before. However, the sequential comparison shows a positive trend, with revenue increasing by 19.786% from $0.36 million. This sequential improvement brings some hope for future growth potential.
|
Edgewell Personal Care Company
Edgewell Personal Care Company, a prominent player in the Personal and Household Products industry, released its financial results for the quarter ended September 30, 2023. The company's performance was a mixed bag, with some positive developments but also areas of concern. Let's delve into the numbers to gain a better understanding of how Edgewell fared during this period. The company reported a loss of $0.17 per share, marking an improvement from the deficit of $0.91 per share recorded in the same quarter the previous year. However, compared to the preceding quarter, where earnings per share stood at $1.01, there was a significant decline.
|
Eos Inc
Eos Inc Struggles to Find Stability Amidst Revenue Drop and Declining Finances In the financial period ending September 30, 2023, Eos Inc disclosed its financial results, showcasing a concerning trend for the struggling company. With balanced books reaching a disappointing $0.00 per share, compared to the same period last year, and the previous financial reporting period, it signals a lack of growth and stability within the organization. The company's revenue took a sharp plunge, declining by a staggering -88.056% to $0.04 million from $0.30 million in the corresponding financial period a year ago. Additionally, the sequential revenue drop was recorded at -56.528% from $0.08 million, indicating a significant decline in product demand and market performance.
|
Nanophase Technologies Corporation
Nanophase Technologies Corporation, a nanomaterials and advanced materials company, has recently witnessed solid gains in its shares. However, the company's financial results for the third quarter of 2023 reveal weak demand, leading to increased losses. This article will interpret the impact of these results on Nanophase Technologies Corporation's future prospects. Financial Results: The third quarter of 2023 financial report presented a mixed picture for Nanophase Technologies Corporation. Despite recording a net loss per share of $-0.03, slightly higher than the previous year's $-0.02, the company's shares saw a solid gain of 7.87% over the past week. However, the company's revenue suffered a significant drop of -22.195%, amounting to $7.53 million, down from $9.68 million a year prior.
|
Per Share |
Current |
Earnings (TTM) |
-0.08 $ |
Revenues (TTM) |
0.74 $
|
Cash Flow (TTM) |
0.01 $ |
Cash |
0.02 $
|
Book Value |
0.08 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-0.08 $
|
Revenues (TTM) |
0.74 $ |
Cash Flow (TTM) |
0.01 $ |
Cash |
0.02 $
|
Book Value |
0.08 $ |
Dividend (TTM) |
0 $ |
|
|
|
|